STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Clinical trials for STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy drug may save eyes from advanced skin cancer
Disease control Recruiting nowThis study tests whether the immunotherapy drug pembrolizumab can shrink or control advanced or recurrent skin cancer near the eye. About 22 adults with this condition will receive the drug and be monitored for tumor response and whether the eye can be saved. The goal is to see i…
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis study tests whether adding BMX-001 to standard care can reduce severe mouth sores caused by chemoradiation in head and neck cancer patients. About 98 participants will receive either BMX-001 or a placebo alongside their usual treatment. The goal is to improve quality of life…
Matched conditions: STAGE III CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK AJCC V8
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated May 17, 2026 01:02 UTC